Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04829344 · ClinicalTrials.gov registry record · Phase 3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

A Phase 3 study of Anesthesia, Local, sponsored by American Genomics.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target
1
Study location

NCT04829344 is a Phase 3 study of Anesthesia, Local that has completed, run by American Genomics. The registered enrollment target is 120 participants, above the 76-participant average among 18 other Anesthesia, Local trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04829344, a Phase 3 study of Anesthesia, Local, has completed, sponsored by American Genomics.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG AG-920

Study Locations (1)

Texas

  • American Genomics Site 2 - McAllen

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-03-30
Est. Completion 2021-05-10
Phase Phase 3

Sponsor

American Genomics

5 total trials

What the Registry Record Tells You About NCT04829344

The ClinicalTrials.gov registry entry for NCT04829344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 18 other Anesthesia, Local trials with a reported enrollment target (58% higher). The listed sponsor is American Genomics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anesthesia, Local appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04829344 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04829344 about?

NCT04829344 is a clinical study titled "A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution". This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.

What is the current status of trial NCT04829344?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2021-03-30. Estimated completion is 2021-05-10.

What conditions does trial NCT04829344 study?

This clinical trial studies the following conditions: Anesthesia, Local.

What interventions are being tested in trial NCT04829344?

The interventions under investigation include: Placebo (DRUG), AG-920 (DRUG).

Who is sponsoring clinical trial NCT04829344?

This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04829344 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anesthesia, Local

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.